Intercept Pharmaceuticals, Inc. (ICPT) News
Filter ICPT News Items
ICPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ICPT News Highlights
- ICPT's 30 day story count now stands at 4.
- Over the past 29 days, the trend for ICPT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BEAT, EYE and MDGL are the most mentioned tickers in articles about ICPT.
Latest ICPT News From Around the Web
Below are the latest news stories about INTERCEPT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ICPT as an investment opportunity.
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should KnowIntercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right NowOverbought stocks are an early indication of a potential correction on a stock; act now if you hold these stocks. |
Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years agoIt is a pleasure to report that the Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) is up 67% in the last quarter. But... |
Madrigal (MDGL) to Raise Capital Via Public Offering of $500MMadrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States. |
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study DataAcquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector. |
Intercept Pharmaceuticals (ICPT) Surges on Acquisition DealIntercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash. |
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?Although Intercept Pharmaceuticals popped higher on a buyout deal, many stakeholders of ICPT stock are left wondering what might have been. |
Why Intercept Pharmaceuticals Stock Is Skyrocketing TodayIntercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices. |
UPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mlnItaly's Alfasigma S.p.A agreed on Tuesday to buy drugmaker Intercept Pharmaceuticals for $794 million as it aims to expand its treatment portfolio in liver diseases and digestive system disorders, and bolster presence in the U.S. The proposed all-cash acquisition would add Intercept's Ocaliva, a treatment for liver disease primary biliary cholangitis, to Alfasigma's portfolio. Alfasigma's acquisition of Intercept and its drug Ocaliva makes "best economic cost sense" given that a larger company can market and commercialize the drug with better margins and scale than a smaller biotech, Jefferies analyst Michael Yee said. |